← All trials
NCT00646607
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2007
- Primary completion
- Apr 1, 2013
- Completion date
- Nov 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 3756
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteLead sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteOverall official - principal investigator
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteStudy chair
- Mario Negri InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.